AbbVie - AI Stock Analysis

Analysis generated November 25, 2025

AbbVie Inc. (NYSE: ABBV) is a global biopharmaceutical company that engages in the research, development, manufacturing, and sale of pharmaceuticals. The company was separated from Abbott Laboratories in 2013 and has since grown into a major player in the industry. AbbVie focuses on various therapeutic areas such as immunology, oncology, neuroscience, virology, and eye care. Some of its well-known products include Humira, Imbruvica, and Venclexta.

Fundamental Analysis

Revenue for the last quarter was $15.8 billion, representing an increase of 2.29% compared to the previous quarter and a significant 9.10% year-over-year growth. These figures demonstrate robust revenue generation and are positive indicators for the company's future prospects.

Net income for the last quarter was reported at $186 million, indicating a sharp decline of 80.30% compared to the previous quarter and an 88.08% decrease year-over-year. This dramatic drop in net income is a cause for concern and warrants further investigation into the underlying factors driving the decline.

EBITDA for the last quarter stood at $1.38 billion, which is 68.21% lower than the previous quarter and 71.72% lower year-over-year. EBITDA is a key measure of a company’s operational performance, and this significant decrease raises red flags about AbbVie's profitability and operational efficiency.

The current Price to Earnings (P/E) ratio is 179, which is relatively high. This may indicate that the stock is overvalued and could lead to a bearish outlook as investors might be paying more for less earnings.

Technical Analysis

Today's stock price is $231.80, marking a 1.67% increase from a month ago, signifying a positive short-term trend. When compared to a year ago, there is a notable increase of 32.49%, indicating a sustained positive long-term trend despite some bearish signs in certain indicators.

The Simple Moving Average (SMA10) is currently 233.27, which is slightly lower than the previous SMA10 of 233.33. This suggests a potential slight downward trend in price movement.

The Relative Strength Index (RSI) stands at 23.1, which is considered to be in the oversold range. This can be interpreted as a bullish indicator, suggesting that the stock might be undervalued and could see a price increase in the near future.

Alternative Data Analysis

AbbVie has 1,144 open positions according to data from popular job boards, and this number has remained stable, indicating a company in a stable hiring position. Employee sentiment about the company is neutral, which suggests no significant internal turmoil or exuberance.

The company’s webpage has seen an estimated 1.3 million visitors, showing a 30% increase in the last couple of months. This is a bullish indicator as it suggests a potential increase in customer interest and engagement.

AbbVie's Instagram page has 47,000 followers with a 7% increase in the last couple of months, while its Twitter account has 79,000 followers with no meaningful change. Increased social media engagement, especially on Instagram, can be an indicator of growing brand awareness and customer interest.

The AI score provided by AltIndex for AbbVie is 62, which is a buy signal, combining fundamental, technical, and alternative data analyses.

Conclusion

AbbVie exhibits strong revenue growth, but the substantial declines in net income and EBITDA highlight concerns about profitability and operational efficiency. The high P/E ratio suggests potential overvaluation. On the technical front, the stock shows a mix of bullish signs despite some bearish indicators. The alternative data analysis paints a generally positive picture with stable job postings, increased web traffic, and growing social media engagement.

Based on the analysis across various metrics, the recommendation would be to cautiously consider purchasing AbbVie stock while keeping an eye on the company's ability to address the profitability concerns. The bullish signals in the alternative data and the positive historical stock trends may weigh favorably for the potential investors.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.